Article info
PDFClinical ethics
Paper
What do we really know about the deliberate use of placebos in clinical practice?
- Correspondence to Dr Pekka Louhiala, Department of Public Health, University of Helsinki, Vuorikatu 17 as 3, Hämeenlinna 13100, Finland; pekka.louhiala{at}helsinki.fi
Citation
What do we really know about the deliberate use of placebos in clinical practice?
Publication history
- Received December 1, 2011
- Revised December 15, 2011
- Accepted January 17, 2012
- First published February 19, 2012.
Online issue publication
April 27, 2016
Article Versions
- Previous version (27 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Other content recommended for you
- Deliberate use of placebos in clinical practice: what we really know
- Clinical use of placebo treatments may undermine the trust of patients: a response to Gold and Lichtenberg
- Patients’ attitudes about the use of placebo treatments: telephone survey
- The ethics of the placebo in clinical practice revisited
- Patient attitudes about the clinical use of placebo: qualitative perspectives from a telephone survey
- Physician perspectives on placebo ethics
- Rethinking the placebo effect
- Placebo effects and the molecular biological components involved
- Prescribing “placebo treatments”: results of national survey of US internists and rheumatologists
- The placebo effect: powerful, powerless or redundant?